Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 89
Rev. bras. med. esporte ; 27(3): 335-337, July-Sept. 2021. tab
Article in English | LILACS | ID: biblio-1288579


ABSTRACT Introduction One of the evaluation factors of human health is bone health, and an evaluation index of bone health is osteoporosis. Sports are an effective way to improve the human body. Objective The paper discusses the effects of different exercise intensities on human bone health. Methods The thesis selected 51 female college students, designed different exercise intensities of fitness running intervention programs, and conducted a 12-month exercise intervention. We divide female college students into three groups. The subjects' bone mineral density (BMD), serum alkaline phosphatase (ALP), and serum osteocalcin (BGP) were tested before and after the experiment. Results The differences in femoral BMD, serum ALP, serum BGP, and lumbar spine BMD of the three groups of volunteers were significant (P<0.05), while the differences in ulna and radius BMD were not significant. Conclusions Sports can promote human bone health. At the same time, the effect of fitness running on human BMD is site-specific. Level of evidence II; Therapeutic studies - investigation of treatment results.

RESUMO Introdução Um dos fatores de avaliação da saúde humana é a saúde óssea, e um índice de avaliação da saúde óssea é a osteoporose. Os esportes são uma forma eficaz de melhorar o corpo humano. Objetivo o artigo discute os efeitos de diferentes intensidades de exercício na saúde óssea humana. Métodos A tese selecionou 51 universitárias, elaborou diferentes intensidades de exercícios em programas de intervenção de corrida de aptidão e conduziu uma intervenção de exercícios de 12 meses. Dividimos as universitárias em três grupos. A densidade mineral óssea (BMD), fosfatase alcalina sérica (ALP) e osteocalcina sérica (BGP) dos indivíduos foram testadas antes e depois do experimento. Resultados As diferenças na DMO femoral, ALP sérica, BGP sérica e DMO da coluna lombar dos três grupos de voluntários foram significativas (P <0,05), enquanto as diferenças na DMO da ulna e rádio não foram significativas. Conclusão O esporte pode promover a saúde óssea humana. Ao mesmo tempo, o efeito da corrida adaptativa na DMO humana é específico do local. Nível de evidência II; Estudos terapêuticos - investigação dos resultados do tratamento.

RESUMEN Introducción Uno de los factores de evaluación de la salud humana es la salud ósea y un índice de evaluación de la salud ósea es la osteoporosis. Los deportes son una forma eficaz de mejorar el cuerpo humano. Objetivo El artículo analiza los efectos de diferentes intensidades de ejercicio en la salud ósea humana. Métodos La tesis seleccionó a 51 estudiantes universitarias, diseñó diferentes intensidades de ejercicio de programas de intervención para correr y realizó una intervención de ejercicio de 12 meses. Dividimos a las estudiantes universitarias en tres grupos. La densidad mineral ósea (DMO), la fosfatasa alcalina sérica (ALP) y la osteocalcina sérica (BGP) de los sujetos se analizaron antes y después del experimento. Resultados Las diferencias en la DMO femoral, la ALP sérica, la BGP sérica y la DMO de la columna lumbar de los tres grupos de voluntarios fueron significativas (P <0,05), mientras que las diferencias en la DMO del cúbito y del radio no fueron significativas. Conclusión Los deportes pueden promover la salud ósea humana. Al mismo tiempo, el efecto de la actividad física en la DMO humana es específico del sitio. Nivel de evidencia II; Estudios terapéuticos: investigación de los resultados del tratamiento.

Humans , Female , Bone and Bones/physiology , Bone Density , Osteocalcin/blood , Alkaline Phosphatase/blood , High-Intensity Interval Training
Braz. arch. biol. technol ; 63: e20190594, 2020. tab, graf
Article in English | LILACS | ID: biblio-1132264


Abstract Chronic kidney disease (CKD) is an important health problem across the world affecting the adult population with an enormous social and economic burden. Calcium regulation is also affected in patients with CKD, and related to several disorders including vascular calcifications, mineral bone disorders, and cardiovascular diseases (CVD). Upper zone of growth plate and cartilage matrix (UCMA) is vitamin K-dependent protein (VKDP) and acts as a calcification inhibitor in the cardiovascular system. The molecular mechanism of UCMA action remains unclear in CKD. In the current study, we aimed to investigate serum total UCMA levels and its association with calcium metabolism parameters in CKD patients including hemodialysis (HD) patients. Thirty-seven patients with CKD stage 3-5, 41 HD patients, and 34 healthy individuals were enrolled in this cross-sectional study. Serum UCMA and calcification related protein levels (Matrix Gla Protein (MGP), Osteocalcin (OC), and Fetuin-A) were analyzed with enzyme-linked immunosorbent assay (ELISA). Calcium mineral disorder parameters (Serum Ca, P, iPTH) were quantified with routine techniques. We, for the first time, report the potential biomarker role of UCMA in CKD including HD. Serum total UCMA levels were significantly higher in patients with CKD including HD patients than the healthy controls. Also, serum UCMA levels showed negative correlations with serum calcium, and eGFR, while showed positive relationships with P, iPTH, MGP, OC. Increased total UCMA levels may have a role in the Ca metabolism disorder and related to the pathogenesis of Vascular Calcification in patients with CKD.

Humans , Male , Female , Adult , Middle Aged , Aged , Osteocalcin/blood , Calcium/metabolism , Renal Insufficiency, Chronic/blood , Matrilin Proteins/blood , Growth Plate/metabolism , Biomarkers/blood , Renal Insufficiency, Chronic/metabolism
J. appl. oral sci ; 28: e20190409, 2020. graf
Article in English | LILACS, BBO | ID: biblio-1090768


Abstract Menopause induces oral bone loss, leading to various oral diseases. Mastication importantly affects bone metabolism in the jawbone. Objective: To analyze the effect of enhanced masticatory force on osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), and mechano-growth factor (MGF) in alveolar bone of ovariectomized rats and to study the mechanics mechanism of the alveolar bone of ovariectomized rats response to enhanced masticatory force. Methodology: Thirty Sprague Dawley rats were randomly divided into three groups: sham-operation group (fat around the removed ovary + normal hard diet), model group (ovariectomy + normal hard diet), and experimental group (ovariectomy + high hard diet). It was a 2-month experiment. Enzyme-linked immunosorbent assay (ELISA) detected serum estradiol (E2), osteocalcin (BGP) and alkaline phosphatase (ALP) in rats. Bone histomorphometric indices in the third molar region of maxilla were detected by micro-CT; protein expressions of OPG, RANKL, and MGF in the third molar region of maxilla was detected by Western blot; and gene expression of OPG, RANKL, and MGF in the third molar region of maxilla was detected by Quantitative Real-Time PCR. Results: Comparing with model group, serum E2 in experimental group increased but not significantly, serum BGP and serum ALP in experimental group decreased but not significantly, OPG in experimental group in alveolar bone increased significantly, RANKL in experimental group in alveolar bone decreased significantly, RANKL/OPG ratio in experimental group decreased significantly, MGF in experimental group in alveolar bone increased significantly, bone volume to total volume fraction increased significantly in experimental group, trabecular thickness increased significantly in experimental group, and trabecular separation decreased significantly in experimental group. Conclusion: Enhanced masticatory force affected the expression of OPG, RANKL, and MGF in alveolar bone of ovariectomized rats, improved the quality of jaw bone of ovariectomized rats, and delayed oral bone loss by ovariectomy.

Animals , Female , Bite Force , Insulin-Like Growth Factor I/analysis , Ovariectomy , RANK Ligand/analysis , Osteoprotegerin/analysis , Alveolar Process/physiopathology , Osteocalcin/blood , Blotting, Western , Polymerase Chain Reaction , Rats, Sprague-Dawley , Alkaline Phosphatase/blood , Estradiol/blood , X-Ray Microtomography , Enzyme-Linked Immunospot Assay
Arq. neuropsiquiatr ; 76(7): 452-458, July 2018. tab
Article in English | LILACS | ID: biblio-950560


ABSTRACT The purpose of this study was to determine the effect of lamotrigine (LTG) and levetiracetam (LEV) as mono- and polytherapy on biochemical markers of bone turnover and bone mineral density in Egyptian adult patients with epilepsy. Methods Forty-eight patients were divided into four groups: two received monotherapy of either LTG or LEV, and the other two groups received polytherapy comprising (valproate [VPA] + LTG or VPA + LEV). Thirty matched healthy participants were included in the study. Participants completed a nutritional and physical activity questionnaire. Biochemical markers of bone and mineral metabolism and bone mineral density of the lumbar spine were measured at baseline and at six months. Results In the LEV monotherapy group, the bone formation markers showed a significant decrease in serum alkaline phosphatase and serum osteocalcin levels while the bone resorption marker showed a significant increase in urinary deoxypyridinoline levels. After six months of treatment, bone mineral density showed a significant decrease in all treated groups, while among monotherapy groups, this significant decrease was more prevalent in the LEV monotherapy group compared with the LTG monotherapy group. Furthermore, there was significant negative correlation between urinary deoxypyridinoline levels and bone mineral density in the LEV monotherapy group. Conclusion Using new generation antiepileptics, LEV monotherapies and polytherapy showed harmful effects on bone but LTG did not.

RESUMO O objetivo deste estudo foi determinar o efeito da lamotrigina (LTG) e levetiracetam (LEV) como mono e politerapia em marcadores bioquímicos de remodelação óssea e densidade mineral óssea em pacientes adultos egípcios com epilepsia. Métodos Quarenta e oito pacientes foram divididos em quatro grupos: dois grupos receberam monoterapia de LTG ou LEV e os outros dois grupos receberam politerapia (valproato [VPA] + LTG ou VPA + LEV). Trinta participantes saudáveis controle foram incluídos no estudo. Os participantes preencheram um questionário nutricional e de atividade física. Marcadores bioquímicos do metabolismo ósseo e mineral e densidade mineral óssea da coluna lombar foram medidos no início e aos seis meses. Resultados No grupo de monoterapia LEV, os marcadores de formação óssea mostraram uma diminuição significativa nos níveis séricos de fosfatase alcalina e osteocalcina sérica, enquanto o marcador de reabsorção óssea mostrou um aumento significativo nos níveis de desoxipiridinolina urinária. Após seis meses de tratamento, a densidade mineral óssea mostrou uma diminuição significativa em todos os grupos tratados, enquanto entre os grupos de monoterapia, esta diminuição significativa foi mais prevalente no grupo de monoterapia LEV em comparação com o grupo de monoterapia LTG. Além disso, houve correlação negativa significativa entre os níveis de desoxipiridinolina urinária e densidade mineral óssea no grupo de monoterapia LEV. Conclusão Utilizando antiepilépticos de nova geração, as monoterapias LEV e a politerapia mostraram efeitos prejudiciais no osso, mas a LTG não.

Humans , Male , Female , Adolescent , Adult , Young Adult , Piracetam/analogs & derivatives , Triazines/adverse effects , Bone Density/drug effects , Valproic Acid/adverse effects , Bone Remodeling/drug effects , Anticonvulsants/adverse effects , Piracetam/administration & dosage , Piracetam/adverse effects , Triazines/administration & dosage , Biomarkers/urine , Biomarkers/blood , Case-Control Studies , Osteocalcin/blood , Valproic Acid/administration & dosage , Drug Therapy, Combination , Epilepsy/drug therapy , Lamotrigine , Levetiracetam , Amino Acids/urine , Anticonvulsants/administration & dosage
Arch. endocrinol. metab. (Online) ; 62(3): 285-295, May-June 2018. tab, graf
Article in English | LILACS | ID: biblio-950068


ABSTRACT Objective: The role of bone markers on insulin resistance (IR) remains controversial. The objective of this study is to evaluate the association between bone mineral density (BMD) and glucose metabolism and investigate if visceral hyperadiposity, evaluated by waist circumference (WC), is an effect modifier of this association. Subjects and methods: Cross-sectional analysis with 468 young adults from the fourth follow-up of the 1978/79 Ribeirão Preto prospective birth cohort, Brazil. BMD, total osteocalcin (OC), fasting plasma glucose and insulin concentrations were assessed. IR, sensitivity (S) and secretion (β) were estimated by homeostasis model assessment (HOMA) indexes. Multiple linear regression models were constructed to estimate the association between BMD and glucose metabolism. Beta coefficient, R2 and p-values were provided. WC was tested as an effect modifier and OC as a confounder. The covariates were selected based on Direct Acyclic Graph. Results: Significant interaction between BMD (femoral neck and proximal femur areas) and WC on glucose metabolism was observed in the adjusted models. Subjects with increased WC presented a positive association between BMD and log HOMA1-IR while an inverse association was found in those with normal WC (femoral neck R2 = 0.17, p = 0.036; proximal femur R2 = 0.16, p = 0.086). BMD was negatively associated with log HOMA2-S in individuals with increased WC and positively in those with normal WC (femoral neck R2 = 0.16, p = 0.042; proximal femur R2 = 0.15, p = 0.097). No significant associations between BMD, log HOMA2-β and OC and glucose metabolism markers were observed. Conclusions: BMD was associated with glucose metabolism, independently of OC, and WC modifies this association.

Humans , Male , Female , Adult , Blood Glucose/metabolism , Bone Density/physiology , Intra-Abdominal Fat/physiology , Waist Circumference/physiology , Immunologic Factors/physiology , Blood Glucose/physiology , Osteocalcin/blood , Cross-Sectional Studies , Fasting , Insulin/blood
Arch. endocrinol. metab. (Online) ; 62(3): 275-284, May-June 2018. tab, graf
Article in English | LILACS | ID: biblio-950062


ABSTRACT Objectives: Obesity is a multifactorial disease characterized by the presence of the pro-inflammatory state associated with the development of many comorbidities, including bone turnover marker alterations. This study aimed to investigate the role of the inflammatory state on bone turnover markers in obese adolescents undergoing interdisciplinary weight loss treatment for one year. Subjects and methods: Thirty four post-pubescent obese adolescents with primary obesity, a body mass index (BMI) greater than > 95th percentile of the CDC reference growth charts, participated in the present investigation. Measurements of body composition, bone turnover markers, inflammatory biomarkers and visceral and subcutaneous fat were taken. Adolescents were submitted to one year of interdisciplinary treatment (clinical approach, physical exercise, physiotherapy intervention, nutritional and psychological counseling). Results: Reduction in body mass, body fat mass, visceral and subcutaneous fat, as well as, an increase in the body lean mass and bone mineral content was observed. An improvement in inflammatory markers was seen with an increase in adiponectin, adiponectin/leptin ratio and inteleukin-15. Moreover, a positive correlation between the adiponectin/leptin ratio and osteocalcin was demonstrated. Further, both lean and body fat mass were predictors of osteocalcin. Negative associations between leptin with osteocalcin, adiponectin with Beta CTX-collagen, and visceral fat with adiponectin were observed. Conclusions: It is possible to conclude that the inflammatory state can negatively influence the bone turnover markers in obese adolescents. In addition, the interdisciplinary weight loss treatment improved the inflammatory state and body composition in obese adolescents. Therefore, the present findings should be considered in clinical practice.

Humans , Male , Female , Adolescent , Adult , Young Adult , Osteocalcin/blood , Leptin/blood , Diet, Reducing , Adiponectin/blood , Exercise Therapy , Obesity/therapy , Biomarkers/blood , Weight Loss , Body Mass Index , Bone Density , Bone Remodeling , Combined Modality Therapy , Resistance Training , Obesity/blood
Actual. osteol ; 13(1): 9-16, Ene - Abr. 2017. tab
Article in Spanish | LILACS | ID: biblio-1118618


Tanto el ranelato de estroncio (RSr) como el denosumab (Dmab) son eficaces en el tratamiento de la osteoporosis (OP) posmenopáusica (PM). El efecto de cada fármaco por separado sobre la densidad mineral ósea (DMO) ha sido estudiado recientemente. Con ambas drogas se observó, al año de tratamiento, un aumento significativo de la DMO en columna lumbar (CL), cuello femoral (CF) y cadera total (CT). En este trabajo comparamos la respuesta densitométrica al año de tratamiento con una y otra droga. Utilizamos los registros de 425 pacientes PMOP tratadas con Dmab y 441 tratadas con RSr. En cada paciente analizamos el porcentaje de cambio; se clasificaron como respondedoras aquellas que mostraron un cambio ≥3%. Adicionalmente se comparó la respuesta en pacientes no previamente tratadas con bifosfonatos (BF-naïve) en comparación con pacientes que habían recibido previamente un BF. Al analizar el grupo completo para Dmab, el porcentaje de pacientes respondedoras fue de 68,4% en CL, 63,3% en CF y 49,3% en CT. Por otro lado, en el grupo de pacientes tratadas con RSr, el porcentaje de respondedoras (53,8% en CL, 40,0% en CF y 35,6% en CT) fue estadísticamente menor. Cuando comparamos la respuesta entre las pacientes BF-naïve que recibieron RSr o Dmab, el Dmab indujo mayor respuesta en CL y CF que el grupo RSr, sin diferencias en CT. Cuando se analizaron los subgrupos BF-previo, las tratadas con Dmab mostraron mayor respuesta en todas las regiones. Conclusión: en pacientes con OP-PM, el tratamiento con Dmab produjo mayores incrementos densitométricos que el RSr, siendo el porcentaje de pacientes respondedoras mayor con Dmab que con RSr. (AU)

Both strontium ranelate (SrR) and denosumab (Dmab) are effective in the treatment of postmenopausal osteoporosis (PMOP). The effect of each drug on bone mineral density (BMD) has been studied separately by us. With both treatments, there was a significant increase after one year of treatment at the lumbar spine (LS) and hip. In this paper we compared the densitometric response after one year of treatment with both drugs used separately. We used the clinical records of 425 PM patients treated with Dmab and 441 treated with SrR. For each patient we analyzed the percentage of change; those who showed a change ≥3% were classified as responders. Additionally, the response was compared in patients not previously treated with bisphosphonates (BP-naïve) compared to patients who had previously received a BP. When analyzing the complete group for Dmab, the percentage of "responders" was 65.2% at the LS, 62.9% at the femoral neck (FN) and 47.4% at the total hip (TH). On the other hand, in the group of patients treated with SrR the percentage of responders (53.8% at the LS, 40.0% at the FN and 35.6% at the TH) was statistically lower. When comparing the response between in BF-naïve patients receiving RSr or Dmab, Dmab induced a greater response at the LS and FN than the RSr group, with no statistical differences at the TH. When the subgroups with prior BP treatment were analyzed, those treated with Dmab showed greater response in all regions. Conclusion: in patients with PMOP treatment with Dmab produced greater densitometric increments than SrR, and the percentage of responders was higher with Dmab than with SrR. (AU)

Humans , Female , Middle Aged , Aged , Aged, 80 and over , Strontium/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Denosumab/therapeutic use , Phosphates/blood , Strontium/administration & dosage , Strontium/chemistry , Vitamin D/administration & dosage , Biomarkers , Bone Density/drug effects , Fractures, Stress/prevention & control , Osteocalcin/blood , Osteoporosis, Postmenopausal/blood , Calcium/administration & dosage , Calcium/blood , Retrospective Studies , Teriparatide/therapeutic use , Densitometry , Diphosphonates/therapeutic use , Alkaline Phosphatase/blood , Bone Density Conservation Agents/therapeutic use , Femur Neck/drug effects , Denosumab/administration & dosage , Treatment Adherence and Compliance , Hip , Lumbosacral Region
Actual. osteol ; 13(1): 28-36, Ene - Abr. 2017. tab
Article in Spanish | LILACS | ID: biblio-1118788


El pico de masa ósea (PMO) se alcanza entre los 20 y 35 años, pero la aposición ósea continúa hasta alcanzar el pico de fortaleza ósea (PFO). Se crea así una ventana entre ambos picos que podría ser evaluada mediante marcadores bioquímicos de recambio óseo, ya que durante dicho período la densidad mineral permanece constante. El objetivo fue determinar el final de la aposición ósea mediante marcadores bioquímicos óseos. Se evaluaron por décadas entre 20 y 49 años de edad 139 sujetos sanos de ambos sexos (69 hombres y 70 mujeres), determinando fosfatasa alcalina ósea (FAO), osteocalcina (OC), propéptido amino terminal del colágeno tipo 1 (P1NP) y telopéptido C-terminal del colágeno tipo 1 (CTX). Los marcadores correlacionan negativamente con la edad (OC: r= -0,3; p<0,01; P1NP: r= -0,4; p< 0,01 y CTX: r= -0,4; p<0,01), exceptuando FAO. En hombres de 20-29 años, P1NP y el CTX fueron significativamente mayores vs. 30-39 años (p<0,05 y p<0,001, respectivamente), y entre 30-39 años vs. de 40-49 años en P1NP y CTX (p<0,05; p<0,001, respectivamente). En mujeres de 20-29 años, P1NP y CTX fueron significativamente mayores vs. 30-39 años (p<0,0001 y p<0,01, respectivamente). Conclusión: los marcadores de remodelado óseo más sensibles y específicos permitirían determinar bioquímicamente el fin de la aposición ósea que se produce entre el PMO y el PFO. Si bien es necesario ampliar el número de sujetos evaluados, los datos que surgen de la presente investigación sentarían las bases para futuros estudios epidemiológicos referidos al fin de la aposición ósea. (AU)

Peak bone mass is achieved between 20-35 years; however bone apposition continues to reach an optimal skeleton strength. The window between peak bone mass and peak bone apposition may be evaluated by biochemical bone turnover markers. The objective of this study was to determine the end of bone apposition through biochemical bone markers in both sexes. A total of 139 subjects (69 men and 70 women) were divided by decades between 20 and 49 years of age. Bone alkaline phosphatase (BAL), osteocalcin (OC), type I collagen propeptide (P1NP) and type I collagen C-terminal telopeptide (CTX) were evaluated. Except BAL, the other bone markers negatively correlated with the age [OC (r= -0.3; p<0.01); P1NP (r= -0.4; p<0.01) and CTX (r= -0.4; p<0.01)]. Regarding men aged 20 to 29 years, P1NP and CTX were significantly higher vs. 30-39 years (p<0.05 y p<0.001, respectively) and. vs. 40-49 years (p<0.05; p<0.001, respectively). In women, the results were similar. Regarding 20-29 years, P1NP and CTX were higher vs. 30-39 years (p<0.001 y p<0.01, respectively). Bone remodeling rate decreases after the third decade, suggesting the end of the apposition period of peak bone mass. Conclusion: The most specific and sensitive bone markers would biochemically determine the end of bone apposition that extends between the peak of bone mass and the peak of bone strength. Although it is necessary to increase the number of subjects evaluated, the data that emerge from the present study would establish the bases for future epidemiological studies referring to the end of bone apposition. (AU)

Humans , Male , Female , Adult , Middle Aged , Young Adult , Bone Resorption/physiopathology , Biomarkers , Osteoblasts/physiology , Osteoclasts/physiology , Osteogenesis/physiology , Bone and Bones/metabolism , Bone Density/physiology , Osteocalcin/blood , Calcium/blood , Age Factors , Bone Remodeling/physiology , Creatinine/blood , Collagen Type I/biosynthesis , Collagen Type I/blood , Densitometry , Alkaline Phosphatase/blood , Osteoporotic Fractures/prevention & control
Clinics ; 71(8): 464-469, Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-794629


OBJECTIVES: Bone marrow adipose tissue has been associated with low bone mineral density. However, no data exist regarding marrow adipose tissue in primary hyperparathyroidism, a disorder associated with bone loss in conditions of high bone turnover. The objective of the present study was to investigate the relationship between marrow adipose tissue, bone mass and parathyroid hormone. The influence of osteocalcin on the homeostasis model assessment of insulin resistance was also evaluated. METHODS: This was a cross-sectional study conducted at a university hospital, involving 18 patients with primary hyperparathyroidism (PHPT) and 21 controls (CG). Bone mass was assessed by dual-energy x-ray absorptiometry and marrow adipose tissue was assessed by 1H magnetic resonance spectroscopy. The biochemical evaluation included the determination of parathyroid hormone, osteocalcin, glucose and insulin levels. RESULTS: A negative association was found between the bone mass at the 1/3 radius and parathyroid hormone levels (r = -0.69; p<0.01). Marrow adipose tissue was not significantly increased in patients (CG = 32.8±11.2% vs PHPT = 38.6±12%). The serum levels of osteocalcin were higher in patients (CG = 8.6±3.6 ng/mL vs PHPT = 36.5±38.4 ng/mL; p<0.005), but no associations were observed between osteocalcin and insulin or between insulin and both marrow adipose tissue and bone mass. CONCLUSION: These results suggest that the increment of adipogenesis in the bone marrow microenvironment under conditions of high bone turnover due to primary hyperparathyroidism is limited. Despite the increased serum levels of osteocalcin due to primary hyperparathyroidism, these patients tend to have impaired insulin sensitivity.

Humans , Male , Female , Adult , Middle Aged , Bone Marrow/metabolism , Insulin Resistance/physiology , Osteocalcin/blood , Adipose Tissue/metabolism , Hyperparathyroidism, Primary/metabolism , Parathyroid Hormone/blood , Reference Values , Blood Glucose/analysis , Bone Marrow/diagnostic imaging , Magnetic Resonance Spectroscopy , Absorptiometry, Photon , Bone Density/physiology , Case-Control Studies , Adipose Tissue/diagnostic imaging , Calcium/blood , Cross-Sectional Studies , Hyperparathyroidism, Primary/etiology , Hyperparathyroidism, Primary/diagnostic imaging , Adipogenesis/physiology , Homeostasis
Einstein (Säo Paulo) ; 13(4): 555-559, Oct.-Dec. 2015. tab, graf
Article in Portuguese | LILACS | ID: lil-770499


ABSTRACT Objective To assess the bone health status of children with cerebral palsy and the therapeutic effect of denosumab in a subgroup of children with cerebral palsy and decreased bone mass. Methods Children with cerebral palsy were evaluated according to their motor disability score (classification system gross motor functions III to V), bone density and bone turnover markers. Dual X-ray energy absorption was used to measure the lumbar spine, and total body, except the head. Thereafter a group of children with cerebral palsy and osteoporosis was treated with denosumab, a fully human monoclonal antibody. Bone turnover markers were measured before and three months after treatment. Results Reduction in bone mineral density was observed, particularly in children with greater impairment evaluated by the motor score. Decreased bone turnover markers were found in a selected group of children three months after exposure to denosumab. Conclusion Bone loss was present in children with significant impairment of motor function, as well as decreased serum levels of bone resorption markers with new forms.

RESUMO Objetivo Avaliar o estado de saúde dos ossos em crianças com paralisia cerebral e o efeito terapêutico do denosumabe em um subgrupo de crianças com paralisia cerebral e redução da massa óssea. Métodos Crianças com paralisia cerebral foram avaliadas de acordo com seu escore de incapacidade motora (sistema de classificação para funções motoras grossas, de III a V), e marcadores de turnover ósseo. Dual de absorção de energia de raios X foi utilizado para medir a coluna lombar e total do corpo menos cabeça. Posteriormente, um grupo de crianças com paralisia cerebral e osteoporose foi tratado com denosumabe, um anticorpo monoclonal totalmente humano. Marcadores de remodelação óssea foram medidos antes e três meses após o tratamento. Resultados Houve uma redução da densidade óssea, particularmente em crianças com maior comprometimento do escore motor; os marcadores de remodelação óssea diminuíram em um grupo selecionado de crianças três meses depois de terem sido expostas ao denosumabe. Conclusão A perda óssea esteve presente em crianças com importante comprometimento das funções motoras, além da redução nos níveis séricos de marcadores de reabsorção óssea com novos tratamentos.

Adolescent , Child , Child, Preschool , Female , Humans , Male , Young Adult , Bone Density Conservation Agents/therapeutic use , Cerebral Palsy/drug therapy , Denosumab/therapeutic use , Osteoporosis/drug therapy , Biomarkers/blood , Bone Density/drug effects , Bone Remodeling/drug effects , Cerebral Palsy/complications , Collagen Type I/blood , Motor Disorders/classification , Organ Dysfunction Scores , Osteocalcin/blood , Osteoporosis/complications , Peptides/blood , Spinal Cord
São Paulo; s.n; 2015. 166 p.
Thesis in Portuguese | LILACS | ID: lil-782203


O tecido adiposo e o osso dialogam entre si e influenciam a homeostase da glicose por meio da ação de seus produtos (leptina, adiponectina e osteocalcina). A insuficiência de vitamina D (VD) pode levar a alterações metabólicas em ambos tecidos. Objetivos: Investigar as relações entre concentrações séricas de 25 hidroxivitamina D [25(OH)D], osteocalcina, adipocinas, marcadores do metabolismo da glicose e estado nutricional em crianças e adolescentes. Métodos: Estudo transversal com 198 indivíduos brasileiros (14 a 18 anos) e 318 norte-americanos (8 a 13 anos). Coleta de sangue (após jejum de 12h) foi realizada para mensurar 25(OH)D, paratormônio (PTH), osteocalcina carboxilada (cOC), adiponectina (A), colesterol total, triglicérides, HDL-c, LDL-c e VLDL-c (amostra brasileira); osteocalcina total (tOC) (amostra norte-americana); glicose, insulina, osteocalcina não-carboxilada (ucOC) e leptina (L) (em ambas as amostras). Marcadores do metabolismo da glicose (HOMA-IR, HOMA- e QUICKI) foram calculados. Nos indivíduos brasileiros, o nível de atividade física foi determinado, e a ingestão alimentar foi mensurada por um Recordatório de 24 horas, repetido em 62,6 por cento da amostra. Resultados: População brasileira Indivíduos com excesso de peso (42,6 por cento ) apresentaram menores concentrações de 25(OH)D, adiponectina, cOC, ucOC, HDL-c e QUICKI, e maiores PTH, leptina, LDL-c, VLDL-c, colesterol total, triglicérides, insulina, HOMA-IR e HOMA-, comparados aos eutróficos (p<0,05)...

Bone and adipose tissue interact and influence glucose homeostasis through the action of their products (leptin, adiponectin and osteocalcin). Vitamin D insufficiency can lead to metabolic alterations in both tissues. Objectives: To investigate the relationships between serum 25 hidroxivitamin D [25(OH)D], osteocalcin, adipokines, markers of glucose metabolism and nutritional status among children and adolescents. Methods: Cross-sectional study with 198 Brazilian (14 to 18 years old) and 318 American (8 to 13 years old) individuals. Blood was collected after 12-hour fasting to measure 25(OH)D, parathyroid hormone (PTH), carboxylated osteocalcin (cOC), adiponectin (A), total cholesterol, triglycerides, HDL-c, LDL-c and VLDL-c (Brazilian sample); total osteocalcin (tOC) (American sample); glucose, insulin, undercarboxylated osteocalcin (ucOC) and leptin (L) (both samples). Markers of glucose metabolism were calculated (HOMA-IR, HOMA- and QUICKI). Among Brazilian individuals, physical activity level was determined and food intake was assessed by a 24-hour food record, repeated in 62.6 per cent of the sample. Results: Brazilian population Individuals with weight excess (42.6 per cent from the total) presented lower serum 25(OH)D, adiponectin, cOC, ucOC, HDL-c and QUICKI, and higher PTH, leptin, LDL-c, VLDL-c, total cholesterol, triglycerides, insulin, HOMA-IR and HOMA-, compared to normal weight individuals (p<0.05)...

Humans , Male , Female , Child , Adolescent , Biomarkers/blood , Glucose/metabolism , Homeostasis , Nutritional Status , Bone and Bones/metabolism , Cross-Sectional Studies , Insulin/blood , Leptin/blood , Osteocalcin/blood
Rio de Janeiro; s.n; 2015. 40 p. ilus.
Thesis in Portuguese | LILACS, BBO | ID: biblio-910242


O tecido ósseo é metabolicamente ativo e sofre um processo contínuo de renovação e remodelação. A osteocalcina é um peptídeo secretado pelos osteoblastos. Apesar de ser primariamente depositada na matriz óssea recém-formada, uma pequena fração entra em circulação na corrente sanguínea, sendo considerada como um marcador de formação óssea e interferir na homeostasia da glicose. O objetivo deste estudo foi investigar se o tratamento periodontal afeta os níveis séricos de osteocalcina em pacientes com DM2 e periodontite crônica severa. 26 pacientes foram divididos em grupo teste (n=13, idade média de 55,8 ± 8,4 anos, 9 homens e 4 mulheres) e controle. (n=13, idade média de 59,4± 8.4, 5 homens e 8 mulheres). O grupo teste recebeu tratamento periodontal e grupo controle nãorecebeu tratamento periodontal imediato. O exame periodontal incluiu medidas de IP (Índice de placa), SS (Sangramento à sondagem), PBS (Profundidade de bolsa à sondagem), NIC (Nível de inserção clínica). Exames laboratoriais incluíram HBA1c, glicemia estimada, glicose, triglicerídeo, colesterol total e frações. A concentração de osteocalcina sérica foi analisada pelo ELISA. O exame periodontal, exames laboratoriais e concentração de osteocalcina foram reavaliados 90 dias após. Os resultados mostraram que não houve alterações significativas nos parâmetros periodontais, exames laboratoriais, e níveis de osteocalcina 90 dias após o tratamento periodontal. Conclusão: o tratamento periodotnal não influenciou nos níveis séricos da osteocalcina em pacientes com diabetes melllitus tipo 2 e periodontite crônica severa.

Bone tissue is metabolically active and undergoes a continuous process of resorption and formation. Osteocalcin is a peptide secreted by osteoblasts. Although primarily deposited in newly formed bone matrix, a small fraction enters into circulation in the bloodstream and is considered as a marker of bone formation and interferes with glucose homeostasis. The aim of this study was to investigate whether periodontal treatment affects serum osteocalcin levels in patients with type 2 diabetes and severe chronic periodontitis. 26 patients were divided into test group (n = 13, mean age 55.8 ± 8.4 years, 9 men and 4 women) and control. (n = 13, mean age 59.4 ± 8.4, 5 men and 8 women). The test group received periodontal treatment and untreated control group. Periodontal examination included PI measures (plaque index), BOP (bleeding on probing), PPD (probing pocket depth), CAL (clinical attachment level). Laboratory tests included HbA1c, glucose, triglyceride, total cholesterol and fractions. The concentration of serum osteocalcin was analyzed by ELISA. Periodontal examination, laboratory tests and concentration of osteocalcin were reassessed after 90 days. The results showed no significant changes in periodontal parameters, laboratory tests, and osteocalcin levels 90 days after periodontal treatment. In conclusion, periodontal treatment did not influence the serum levels of osteocalcin in patients with type 2 diabetes and severe chronic periodontitis.

Humans , Male , Female , Middle Aged , Aged , Chronic Periodontitis/etiology , Diabetes Mellitus, Type 2/blood , Osteocalcin/blood , Periodontics , Biomarkers , Blood Glucose , Periodontal Index
J. pediatr. (Rio J.) ; 90(6): 624-631, Nov-Dec/2014. tab, graf
Article in English | LILACS | ID: lil-729835


OBJECTIVE: To study bone mineral density (BMD) in adolescent females according to five groups of chronological age (CA), bone age (BA), and breast development stage (B), and to correlate these parameters with plasma bone biomarkers (BB). METHODS: This was a cross-sectional study performed in 101 healthy adolescent females between 10 and 20 years old. The study variables were: weight, height, body mass index (BMI), CA, B, BA, calcium intake, BMD, and BB. Osteocalcin (OC), bone alkaline phosphatase (BAP), and C-terminal telopeptide (S-CTx) were evaluated for BB. BMD was measured using dual energy X-ray absorptiometry (DXA). RESULTS: BMD in lumbar spine, proximal femur, and total body increased with age, and the respective observed averages were: in CA1 (10 years old), 0.631, 0.692, 0.798 g/cm2; in CA2 (11 to 12 years old), 0.698, 0.763, 0.840 g/cm2; in CA3 (13 to 14 years old), 0.865, 0.889, 0.972 g/cm2; in CA4 (15 to 16 years old), 0.902, 0.922, 1.013 g/cm2; and in CA5 (17 to 19 years old), 0.944, 0.929, 1.35 g/cm2. These results showed significant differences between 13 and 14 years of age (CA3) or when girls reached the B3 stage (0.709, 0.832, 0.867 g/cm2). The highest median concentrations of BB were between 10 and 12 years of age when adolescents were in the B2-B3 (p < 0.001). Median BB concentrations decreased in advanced BA and B. CONCLUSIONS: BB concentrations were positively correlated with the peak height velocity and negatively correlated with BMD in the study sites. Increased BMD and BB concentrations were observed in B3. .

OBJETIVO: Avaliar a densidade mineral óssea (DMO) em adolescentes do sexo feminino de acordo com a idade cronológica (IC), idade óssea (IO) e desenvolvimento das mamas (M) e suas correlações com biomarcadores de remodelação óssea em plasma (BO). MÉTODOS: Este foi um estudo transversal prospectivo feito em 101 adolescentes saudáveis do sexo feminino com idade entre 10 e 20 anos. As variáveis estudadas foram: peso, altura, índice de massa corpórea (IMC), IC, IO, M, ingestão de cálcio, DMO e BO. A osteocalcina (OC), fosfatase alcalina óssea (BAP) e o telopeptídeo C terminal (S-CTx) foram os biomarcadores de remodelação óssea avaliados. A DMO foi obtida por absorciometria de raios-X de dupla energia (DXA). RESULTADOS: A DMO de coluna lombar, fêmur proximal e corpo total aumentou com a idade, e as respectivas médias observadas foram: IC1 = 0,631, 0.692, 0,798 g/cm2; IC2, 0,698, 0,763, 0,840 g/cm2; IC3, 0,865, 0,889, 0,972 g/cm2; IC4, 0,902, 0,922, 1,013 g/cm2; e IC5, 0,944, 0,929, 1,35 g/cm2. Observou-se diferença significativa entre 13 e 14 anos (IC3) ou quando as meninas estavam em M3 (0,709, 0,832, 0,867 g/cm2). Os valores dos BO apresentaram elevação entre 10 e 12 anos e quando as adolescentes estavam em M2-M3 (p < 0,001). Os valores das medianas dos BO diminuíram com o avançar da IO e M. CONCLUSÕES: Os BOs mostraram paralelismo com o pico de velocidade de crescimento e demonstraram correlação negativa com a DMO no sítios avaliados. O aumento da DMO e dos BOs foi observado em M3. .

Adolescent , Child , Female , Humans , Young Adult , Bone Density/physiology , Breast/physiology , Puberty/physiology , Age Factors , Alkaline Phosphatase/blood , Body Mass Index , Biomarkers/blood , Bone Remodeling/physiology , Breast/growth & development , Cross-Sectional Studies , Osteocalcin/blood , Prospective Studies , Students
Arq. bras. endocrinol. metab ; 58(5): 444-451, 07/2014. graf
Article in English | LILACS | ID: lil-719200


Osteocalcin is a bone matrix protein that has been associated with several hormonal actions on energy and glucose metabolism. Animal and experimental models have shown that osteocalcin is released into the bloodstream and exerts biological effects on pancreatic beta cells and adipose tissue. Undercarboxylated osteocalcin is the hormonally active isoform and stimulates insulin secretion and enhances insulin sensitivity in adipose tissue and muscle. Insulin and leptin, in turn, act on bone tissue, modulating the osteocalcin secretion, in a traditional feedback mechanism that places the skeleton as a true endocrine organ. Further studies are required to elucidate the role of osteocalcin in the regulation of glucose and energy metabolism in humans and its potential therapeutic implications in diabetes, obesity and metabolic syndrome.

A osteocalcina é uma proteína da matriz óssea que tem sido implicada com várias ações hormonais relacionadas à homeostase de glicose e ao metabolismo energético. Modelos animais e experimentais têm demonstrado que a osteocalcina é liberada do osso para a circulação sanguínea e age nas células betapancreáticas e no tecido adiposo. A osteocalcina decarboxilada é a isoforma hormonalmente ativa e estimula a secreção e sensibilidade à insulina no tecido adiposo e muscular. A insulina e a leptina, por sua vez, atuam no tecido ósseo modulando a secreção da osteocalcina, formando uma alça de retroalimentação tradicional em que o esqueleto torna-se um órgão endócrino. Novos estudos ainda são necessários para elucidar o papel da osteocalcina na regulação glicêmica e no metabolismo energético em humanos, com potenciais implicações terapêuticas no tratamento de diabetes, obesidade e síndrome metabólica.

Animals , Humans , Energy Metabolism/physiology , Glucose/metabolism , Osteocalcin/physiology , Adipose Tissue/metabolism , Bone and Bones/metabolism , /metabolism , Insulin Resistance , Insulin-Secreting Cells/metabolism , Insulin/metabolism , Leptin/metabolism , Metabolic Syndrome/metabolism , Muscles/drug effects , Obesity/metabolism , Osteocalcin/blood
Arch. latinoam. nutr ; 64(1): 24-33, mar. 2014. ilus, tab
Article in Spanish | LILACS | ID: lil-752688


La información sobre biomarcadores óseos en adolescentes y adultas durante el periodo posparto es incierta, por lo que el objetivo de este artículo fue analizar el patrón de biomarcadores óseos en adolescentes y adultas a 15, 90, 180 y 365 días posparto (dpp) y su asociación con la densidad mineral ósea (DMO) y lactancia materna. Se realizó un estudio de cohorte en 32 madres adolescentes ≤17 años y 41 adultas de 18 a 29 años de edad en el primer año posparto. Se realizaron medidas antropométricas, DMO y biomarcadores óseos y así como datos del tipo y la duración de lactancia. Como resultados se encontró asociación entre la concentración basal de N-telopéptidos ≤24 μg/L y mayor aumento de DMO. Las adolescentes tuvieron mayor concentración de N-telopéptidos (p≤0.004) y menor concentración de osteocalcina (5±3 vs13±4, p <0.001) que las adultas. La lactancia no afectó el cambio de DMO (p>0.050), ni de biomarcadores óseos. La osteocalcina se asoció con el cambio en DMO (p<0.040). La prolactina fue mayor entre las que practicaron lactancia materna exclusiva (p<0.001). A menor edad menores concentraciones de osteocalcina (p<0.001) y mayores concentraciones de N-telopéptidos (p<0.001). Se concluyó que a menor concentración de N-telopéptidos y mayor de osteocalcina hubo un mayor aumento de DMO, lo cual implica menor aumento de ésta en el grupo de adolescentes. La lactancia no afectó la DMO.

The objective of this study was to describe the trend of bone biomarkers in adults and adolescents women at 15, 90, 180 and 365 postpartum days (ppd) and its relation with bone mineral density (BMD). It was a prospective cohort of 32 teenager’s ≤17 and 41 women from 18 to 29 years old. We evaluated diet, anthropometry, BMD, bone biomarkers and hormonal profile. In all, the concentration of N-telopeptide was higher at 15 days postpartum decreasing during first year postpartum, but adolescents had the highest concentration. The lowest N-telopeptide concentration was associated with highest increasing of the BMD. Osteocalcin concentration was lower in adolescents than in adults women (5 ± 3 vs 13 ± 4 ng/mL, p<0.001) during first year postpartum. Exclusive breastfeeding did not affect the BMD (p>0.050) or bone biomarkers. Osteocalcin concentration was positively associated with bone BMD (p<0.040), breastfeeding did not affect osteocalcin concentrations. Prolactin was higher among women who breastfed exclusively (p<0.001). Age and breastfeeding inversely correlated with bone biomarkers (p<0.001) N-telopeptide and PTHi respectively. We concluded that a lower N-telopeptide concentration and a higher osteocalcin concentration were associated with a higher increasing of BMD, so then, adolescents showed the lowest recovery of the BMD. Breastfeeding does not affect the BMD.

Adolescent , Adult , Female , Humans , Male , Young Adult , Bone Density/physiology , Collagen Type I/blood , Lactation/blood , Osteocalcin/blood , Peptides/blood , Postpartum Period/blood , Absorptiometry, Photon , Biomarkers/blood , Cohort Studies , Lactation/physiology , Postpartum Period/physiology
Medicina (B.Aires) ; 73(5): 428-432, oct. 2013. graf, tab
Article in Spanish | LILACS | ID: lil-708529


El objetivo de este trabajo retrospectivo fue evaluar el tratamiento de la osteoporosis grave con teriparatide (PTH) y comparar nuestros resultados con los publicados en la literatura médica. Se incluyeron cuarenta y seis pacientes, cuarenta y dos mujeres y cuatro varones, edad: 69.15 ± 9.43 años. Seis eran vírgenes de tratamiento y cuarenta tratados previamente con bisfosfonatos. Treinta y dos pacientes habían tenido 93 fracturas de las cuales 86 vertebrales. Cuarenta y seis recibieron PTH 6 meses, 29 pacientes durante 12 meses y 20 completaron los 18 meses sugeridos. La densidad mineral ósea (DMO) de columna lumbar aumentó significativamente desde el primer control a los 6 meses (p < 0.0001). La DMO de cuello de fémur alcanzó un incremento significativo al final del tratamiento (p = 0.002). La osteocalcina aumentó significativamente al mes, seguido por el ß crosslaps (beta-CTx, prueba en suero) al tercer mes y la fosfatasa alcalina ósea, regresando los marcadores de recambio óseo a niveles basales a los 18 meses. Las calcemias y las calciurias no se modificaron significativamente, pero 8 pacientes tuvieron hipercalcemias leves y tres hipercalciurias asintomáticas. El tratamiento fue bien tolerado y no se registraron efectos adversos graves que requirieran suspender el tratamiento. En conclusión, la PTH es una alternativa útil y segura para el tratamiento de la osteoporosis grave. Nuestros resultados concuerdan con los previamente publicados en la literatura médica.

The primary objective of this retrospective study was to evaluate the treatment of severe osteoporosis with teriparatide (PTH) and to compare our results with those published in the literature. We included 46 patients, 42 women and four men, mean age: 69.15 ± 9.43 years. Six patients were treatment naive and forty previously treated with bisphosphonates. Thirty-two patients had had 93 fractures of which 86 vertebral. Forty-six received PTH for 6 months, twenty-nine for 12 months and twenty completed the 18 months suggested. Bone mineral density (BMD) of the lumbar spine increased significantly at the first control performed at six months of treatment (p < 0.0001), and the femoral neck BMD reached a significant increase at the end of treatment (p = 0.002). Serum osteocalcin values significantly increased from the first month of treatment, followed by ß crosslaps (beta-CTx, serum test) and bone-specific alkaline phosphatase, returning all the markers of bone turnover to baseline levels at 18 months. Serum and urinary calcium did not change significantly at any time, but 8 (17.9%) patients developed mild hypercalcemia and 3 (6.5%) asymptomatic hypercalciuria. The treatment was well tolerated and there were no serious adverse events requiring discontinuation. In conclusion, PTH is a safe and useful alternative for the treatment of primary severe osteoporosis. Our results agree with those previously reported in the literature.

Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Bone Density Conservation Agents/therapeutic use , Osteoporosis/drug therapy , Teriparatide/therapeutic use , Alkaline Phosphatase/blood , Bone Density , Calcium/blood , Calcium/urine , Diphosphonates/therapeutic use , Osteocalcin/blood , Osteoporosis/blood , Retrospective Studies , Severity of Illness Index , Statistics, Nonparametric , Time Factors , Treatment Outcome
Clinics ; 68(10): 1338-1343, out. 2013. tab, graf
Article in English | LILACS | ID: lil-689985


OBJECTIVE: Accelerated bone loss that occurs in postmenopausal women has been linked to oxidative stress and increased free radicals. We propose the use of antioxidants to prevent and reverse postmenopausal osteoporosis. This study aimed to examine the effects of tocotrienol, a vitamin E analog, on bone loss due to estrogen deficiency. Our previous study showed that tocotrienol increased the trabecular bone volume and trabecular number in ovariectomized rats. In the current study, we investigated the effects of tocotrienol supplementation on various biochemical parameters in a postmenopausal osteoporosis rat model. MATERIALS AND METHODS: A total of 32 female Wistar rats were randomly divided into four groups. The baseline group was sacrificed at the start of the study, and another group was sham operated. The remaining rats were ovariectomized and either given olive oil as a vehicle or treated with tocotrienol at a dose of 60 mg/kg body weight. After four weeks of treatment, blood was withdrawn for the measurement of interleukin-1 (IL1) and interleukin-6 (IL6) (bone resorbing cytokines), serum osteocalcin (a bone formation marker) and pyridinoline (a bone resorption marker). RESULTS: Tocotrienol supplementation in ovariectomized rats significantly reduced the levels of osteocalcin, IL1 and IL6. However, it did not alter the serum pyridinoline level. CONCLUSION: Tocotrienol prevented osteoporotic bone loss by reducing the high bone turnover rate associated with estrogen deficiency. Therefore, tocotrienol has the potential to be used as an anti-osteoporotic agent in postmenopausal women. .

Animals , Female , Humans , Rats , Antioxidants/therapeutic use , Dietary Supplements , Osteoporosis, Postmenopausal/drug therapy , Tocotrienols/therapeutic use , Amino Acids/blood , Body Weight , Biomarkers/blood , Bone Resorption/drug therapy , Bone Resorption/prevention & control , Eating , Interleukin-1/blood , /blood , Ovariectomy , Osteocalcin/blood , Osteoporosis, Postmenopausal/prevention & control , Random Allocation , Rats, Wistar , Time Factors , Treatment Outcome
Pakistan Journal of Pharmaceutical Sciences. 2013; 26 (5): 1027-1031
in English | IMEMR | ID: emr-138426


Cosmos caudatus [ulam raja] contains high mineral content and possesses high antioxidant activity which may be beneficial in bone disorder such as postmenopausal osteoporosis. The effects of C. caudatus on bone metabolism biomarkers in ovariectomized rats were studied. 48 Sprague-Dawley rats aged three months were divided into 6 groups. One group of rats was sham-operated while the remaining rats were ovariectomized. The ovariectomized rats were further divided into 5 groups: the control, three groups force-fed with C. caudatus at the doses of 100mg/kg, 200mg/kg or 300mg/kg and another group supplemented with calcium 1% ad libitum. Treatments were given 6 days per week for a period of eight weeks. Blood samples were collected twice; before and after treatment. Parameters measured were bone resorbing cytokine; interleukin-1 and the bone biomarkers; osteocalcin and pyridinoline. Serum IL-1 and pyridinoline levels were significantly increased in ovariectomized rats. Supplementation of C. caudatus was able to prevent the increase of IL-1 and pyridinoline in ovariectomized rats. Besides that, C. caudatus showed the same effect as calcium 1% on biochemical parameters of bone metabolism in ovariectomized rats. In conclusion, Cosmos caudatus was as effective as calcium in preventing the increase in bone resorption in ovariectomized rats

Animals , Female , Ovariectomy , Osteoporosis/drug therapy , Phytotherapy , Plant Extracts/pharmacology , Plants, Medicinal , Bone Remodeling/drug effects , Bone and Bones/drug effects , Calcium/pharmacology , Dietary Supplements , Disease Models, Animal , Rats, Sprague-Dawley , Time Factors , Interleukin-1/blood , Osteocalcin/blood
Egyptian Journal of Histology [The]. 2013; 36 (3): 646-659
in English | IMEMR | ID: emr-187233


Introduction: Osteoporosis is the most common skeletal disorder that has become a leading cause of morbidity and mortality worldwide. Its prophylaxis and therapy are still unresolved challenges

Aim of the study: The aim of the study was to investigate the possibility that collagen hydrosylate [CH] can ameliorate osteoporotic bone loss in ovariectomized rats with special reference to bone mineral content [BMC], some biochemical parameters of bone turnover, and histology

Materials and methods: Forty adult female albino rats [180-200 g] were categorized into four equal groups: a sham-operated control group [group I], a sham-operated CH-treated group [group II], an ovariectomized group [group III], and a CH-treated ovariectomized group [group IV]. The experiment continued for 12 weeks. At its end, the animals were sacrificed under anesthesia. Blood samples were collected for estimation of serum calcium, osteocalcin, bone-specific alkaline phosphatase, and C-terminal telopeptide of type I collagen [CTX]. The left femora and lumbar vertebrae were excised for histological examination by H and E and Gomori's trichrome stains. The area percentage of collagen was further assessed using an image analyzer. The right femur of each rat was used for BMC measurement by energy-dispersive X-ray analysis

Results: In sham-operated CH-treated rats [group II] there was no significant variation in bone turnover markers and BMC as compared with their respective controls. Normal bone microstructure was depicted as well. In group III rats, ovariectomy [OVX] was associated with enhanced bone turnover as depicted by significant decrease in the mean value of serum calcium, whereas osteocalcin, bone-specific alkaline phosphatase, and CTX revealed significant increase compared with controls. Moreover, an evident reduction in bone calcium content was depicted in the femora of this group. Histologically, evidence of bone resorption was manifested in the femoral diaphysis and lumbar vertebrae with multiple resorption cavities, irregularly eroded endosteal surface containing osteoclasts, and thinned out bone trabeculae along with wide bone marrow cavities. A significant decrease in bone collagen content of both cortical and trabecular bones was evidenced in trichrome-stained sections. In contrast, CH administration after OVX [in group IV] reduced bone turnover markers and improved BMC as well as histological characteristics of examined bones as compared with the OVX group

Conclusion: The study suggested that CH may be a potentially useful agent in preventing bone loss due to ovarian hormone deficiency

Female , Animals, Laboratory , Femur/pathology , Lumbar Vertebrae/pathology , Histology , Rats , Collagen/therapeutic use , Osteocalcin/blood , Osteoporosis
West Indian med. j ; 61(6): 627-630, Sept. 2012. tab
Article in English | LILACS | ID: lil-672969


Glucocorticoids have been used in nephrotic syndrome (NS) treatment for many years. In this study, we aimed to evaluate the effect of steroids on bone mineralization in children with glucocorticoid-sensitive nephrotic syndrome (GSNS). Twenty children who were first diagnosed as GSNS received glucocorticoid therapy for four months. Before treatment, at the 4th and 12th week of initial therapy, bone mineral density (BMD) and levels of the markers for bone turnover were evaluated. At the 4th and 12th week of treatment, mean serum calcium (Ca) and osteocalcin levels were found to be significantly lower than those at the beginning ofthe therapy. Mean serum total alkaline phosphatase (t-ALP), bone-specific alkaline phosphatase (b-ALP) and urine calcium creatinine ratio (Ca/Cr), urinary deoxypyridinoline levels were significantly increased in comparison to the beginning of therapy. There was no significant relationship between serum levels of phosphate and parathyroid hormone (PTH) at the beginning of treatment and at the 4th and 12th week of treatment. Mean value of BMD was significantly lower at the 4th and 12th week of treatment than that at the beginning of the therapy. In conclusion, bone mineralization was negatively affected by steroid treatment in children with NS. These children should undergo regular BMD evaluation, and an appropriate therapeutic approach should be planned.

Por muchos años se han venido usando glucocorticoides en el tratamiento del síndrome nefrótico (SN). Este estudio se encamina a evaluar el efecto de los esteroides sobre la mineralización ósea en niños con síndrome nefrótico sensible a los glucocorticoides (SNSG). Veinte niños que fueron diagnosticados primeramente con SNSG, recibieron terapia con glucocorticoides durante cuatro meses. Antes del tratamiento, en las semanas 4 y 12 de la terapia inicial, se evaluaron la densidad mineral ósea (DMO) y los niveles de los marcadores del recambio óseo. En el tratamiento de las semanas 4 y 12, se halló que el calcio (Ca) sérico promedio y los niveles de osteocalcina eran significativamente más bajos que los existentes a comienzos de la terapia. Los niveles de fosfatasa alcalina sérica total promedio, fosfatasa alcalina (t-ALP), fosfatasa alcalina especifica ósea media (b-ALP), la relación calcio/creatinina en la orina (Ca/Cr), y los niveles de deoxipiridinolina urinaria, aumentaron significativamente en comparación con los existentes al comienzo de la terapia. No hubo relación significativa alguna entre los niveles séricos de fosfato y hormona paratiroidea (PTH) ni al principio del tratamiento ni en las semanas 4 y 12 de tratamiento. El valor promedio de la DMO fue significativamente más bajo en las semanas 4 y 12 de tratamiento que al principio de la terapia. En conclusión, la mineralización del hueso fue afectada negativamente por el tratamiento con esteroides en los niños con SN. Estos niños deben tener una evaluación regular de DMO, para lo cual es necesario planear un enfoque terapéutico apropiado.

Child , Child, Preschool , Female , Humans , Male , Bone Density/drug effects , Glucocorticoids/pharmacology , Nephrotic Syndrome/drug therapy , Prednisolone/pharmacology , Alkaline Phosphatase/blood , Amino Acids/urine , Biomarkers/blood , Bone Density/physiology , Bone and Bones/metabolism , Calcium/blood , Calcium/urine , Creatinine/urine , Glucocorticoids/therapeutic use , Osteocalcin/blood , Prednisolone/therapeutic use